Skip to main content

Table 4 Association between cord blood concentrations of PFASs and risk for childhood AD (n = 687)

From: Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and childhood atopic dermatitis: a prospective birth cohort study

PFASs

Number

Number of cases

Crude OR (95%CI)

Adjusted OR (95%CI)

p for sex-PFASs interaction

PFOS

 Continuousa

687

173

1.17 (0.85–1.62)

1.23 (0.85–1.76)

0.33

 Q1 (< 1.81)b

171

40

1

1

0.26

 Q2 (1.81–2.48)

172

42

1.06 (0.64–1.74)

0.93 (0.56–1.58)

 

 Q3 (2.48–3.24)

172

41

1.03 (0.62–1.69)

1.00 (0.59–1.70)

 

 Q4 (≥ 3.24)

172

50

1.34 (0.83–2.18)

1.31 (0.78–2.20)

 

 p for trendc

  

0.27

0.27

 

PFOA

 Continuousa

687

173

1.44 (1.02–2.03)

1.35 (0.93–1.97)

0.17

 Q1 (< 4.94)b

171

34

1

1

0.14

 Q2 (4.94–6.98)

172

46

1.47 (0.89–2.44)

1.48 (0.87–2.52)

 

 Q3 (6.98–9.55)

172

39

1.18 (0.70–1.98)

1.16 (0.67–2.00)

 

 Q4 (≥ 9.55)

172

54

1.84 (1.12–3.02)

1.74 (1.02–2.95)

 

 p for trendc

  

0.04

0.1

 

PFNA

 Continuousa

687

173

1.49 (0.95–2.32)

1.53 (0.94–2.47)

0.46

 Q1 (< 0.50)b

171

36

1

1

0.33

 Q2 (0.50–0.64)

172

44

1.29 (0.78–2.13)

1.15 (0.67–1.97)

 

 Q3 (0.64–0.83)

172

44

1.29 (0.78–2.13)

1.20 (0.71–2.05)

 

 Q4 (≥ 0.83)

172

49

1.49 (0.91–2.45)

1.47 (0.87–2.50)

 

 p for trendc

  

0.13

0.15

 

PFDA

 Continuousa

687

173

1.18 (0.93–1.50)

1.22 (0.94–1.58)

0.65

 Q1 (< 0.23)b

171

40

1

1

0.68

 Q2 (0.23–0.36)

172

36

0.87 (0.52–1.44)

0.94 (0.55–1.60)

 

 Q3 (0.36–0.54)

172

45

1.16 (0.71–1.90)

1.15 (0.68–1.95)

 

 Q4 (≥ 0.54)

172

52

1.42 (0.88–2.30)

1.58 (0.94–2.65)

 

 p for trendc

  

0.08

0.06

 

PFUA

 Continuousa

687

173

1.18 (0.86–1.63)

1.24 (0.88–1.75)

0.67

 Q1 (< 0.29)b

171

40

1

1

0.83

 Q2 (0.29–0.40)

172

40

0.99 (0.60–1.64)

1.01 (0.59–1.71)

 

 Q3 (0.40–0.53)

172

44

1.13 (0.69–1.84)

1.13 (0.67–1.90)

 

 Q4 (≥ 0.53)

172

49

1.31 (0.80–2.12)

1.36 (0.81–2.28)

 

 p for trendc

  

0.23

0.22

 

PFDoA

 Continuousa

687

173

0.96 (0.70–1.30)

1.00 (0.72–1.39)

0.28

 Q1 (≤ 0.069)b

171

36

1

1

0.76

 Q2 (0.069–0.094)

172

54

1.72 (1.05–2.80)

1.83 (1.09–3.08)

 

 Q3 (0.094–0.125)

172

42

1.21 (0.73–2.01)

1.37 (0.80–2.34)

 

 Q4 (≥ 0.125)

172

41

1.17 (0.71–1.95)

1.18 (0.68–2.04)

 

 p for trendc

  

0.93

0.87

 

PFHxS

 Continuousa

687

173

1.31 (0.80–2.13)

1.08 (0.62–1.85)

0.43

 Q1 (≤ 0.13)b

171

37

1

1

0.05

 Q2 (0.13–0.16)

172

43

1.21 (0.73–1.99)

1.25 (0.74–2.12)

 

 Q3 (0.16–0.20)

172

46

1.32 (0.81–2.17)

1.15 (0.68–1.94)

 

 Q4 (≥ 0.20)

172

47

1.36 (0.83–2.23)

1.14 (0.67–1.94)

 

 p for trendc

  

0.2

0.73

 

PFBS

 Continuousa

687

173

1.20 (0.87–1.66)

1.22 (0.87–1.72)

0.83

 Q1 (≤ 0.037)b

170

39

1

1

0.33

 Q2 (0.037–0.047)

171

43

1.13 (0.69–1.86)

1.28 (0.75–2.17)

 

 Q3 (0.047–0.062)

174

46

1.21 (0.74–1.97)

1.18 (0.70–2.00)

 

 Q4 (≥ 0.062)

172

45

1.19 (0.73–1.95)

1.15 (0.68–1.95)

 

 p for trendc

  

0.46

0.70

 
  1. Models were adjusted for all the confounders followed, maternal age (continuous), maternal pre-pregnancy BMI (continuous), gestational week at delivery (continuous), birth weight (categorical), maternal education (categorical), paternal education (categorical), parity (categorical), mode of delivery (categorical), family history of allergic disorders (categorical), infant sex (categorical), family income (categorical), maternal ethnicity (categorical), paternal smoking (categorical) and breastfeeding (categorical)
  2. aLog-transformed PFASs as continuous variables
  3. bReference category
  4. cp-Values for exposure were modeled according to the median value of each quartile